

In re application of:

Rudiger Ridder, *et al.*

Appl. No. 10/633,484

Filed: July 31, 2003

For: METHOD FOR SOLUTION BASED  
DIAGNOSIS



Art Unit: 1643

Examiner: Not Yet Assigned

Atty. Docket: 05033.0003.00US00

Confirmation No. 6405

### Information Disclosure Statement

Mail Stop Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted

to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120.  
1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
  - ☐ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
  - ☐ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
  - c. Before the mailing date of a first Office Action on the merits;
  - ☐ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
  - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
  - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
  - ☐ c. The U.S. Patent and Trademark Office is hereby authorized to charge 180.00 to our Deposit Account No. 08-3038 referencing docket number 05033.0003.00US00 under 37 C.F.R. § 1.17(p).

- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. § 1.17(i), and
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. \_\_\_\_\_, filed \_\_\_\_\_, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. \_\_\_\_\_, filed \_\_\_\_\_, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05033.0003.00US00.

Respectfully submitted,



Date: June 15, 2006

---

Viola T. Kung (Reg. No. 41,131)  
Elisabeth Evertsz (Reg. No. 50,304)

**HOWREY LLP**

2941 Fairview Park Drive  
Box 7  
Falls Church, VA 22042  
Ph. (650) 798-3600  
Fax (650) 798-3570

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**PTO FORM 1449**

ATTY. DOCKET NO.

05033.0003.00US00

APPLICATION NO.

10/633,484

APPLICANT

RIDDER, R., *et al.*,

FILING DATE

July 31, 2003

GROUP

1643

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	US 4,281,061	07-1981	Zuk <i>et al.</i> ,			
	2.						
	3.						

**FOREIGN PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	4.							
	5.							

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, Etc.)

	6.	He, <i>et al.</i> , "Expression, Deletion And Mutation of p16 Gene in Human Gastric Cancer" <i>World J. of Gastroenterology</i> <u>7</u> (4): 515-521 (2001)					
	7.	Myung, <i>et al.</i> , "Loss Of p16 And p27 Is Associated With Progression Of Human Gastric Cancer" <i>Cancer Letters</i> <u>153</u> :129-136 (2000)					
	8.	Nakao <i>et al.</i> , "Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation" <i>British J of Cancer</i> <u>75</u> (10):1410-1416, 1997					
	9.	O'Nions, <i>et al.</i> , "p73 Is Over-Expressed In Vulval Cancer Principally As The $\Delta 2$ Isoform" <i>British J. Cancer</i> <u>85</u> (10):1551-1556 (Nov 2001)					
	10.	Sano, <i>et al.</i> , "Overexpression Of P16 And P14ARF Is Associated With Human Papillomavirus Infection In Cervical Squamous Cell Carcinoma And Dysplasia" <i>Pathology Int.</i> <u>52</u> :375-383 (May 2002)					
	11.	Sherr, "The Ink4a/Arf Network In Tumor Suppression" <i>Nature Reviews Mol. Cell Bio</i> <u>2</u> :731-737, (2001)					
	12.	Takeuchi, <i>et al.</i> , "Altered p16/MTSi/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With The Prognosis of Squamous Cell Carcinoma of the Esophagus" <i>Clinical Cancer Research</i> <u>3</u> :2229-2236, (1997)					
	13.	Tsuji, <i>et al.</i> , "Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer" <i>Oncology</i> <u>58</u> :126-136 (2000)					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.